Literature DB >> 15382281

Vincristine neuropathy: neurophysiological and genetic studies in a case of Wilms tumor.

Amalia Schiavetti1, Massimo Frascarelli, Stefania Uccini, Antonio Novelli.   

Abstract

We report a 10-year-old female with Wilms tumor (WT) who developed severe neuropathy after the fifth weekly dose of vincristine. The girl was previously asymptomatic and the family history was negative for inherited neuropathies. Neurophysiological studies and electrodiagnostic findings were suggestive of a axonal neuropathy with greater motor than sensory characteristics not typical of Charcot-Marie-Tooth (CMT) Type 1A. Genetic studies were performed in view of the degree of neurotoxicity. Duplication of 17p11.2 was found that supported the diagnosis of CMT Type 1A. The patient is alive without disease and with minimal weakness of the lower extremities after 42 months. Neurophysiological studies, repeated at 8 and 24 months, were negative. Although the association of asymptomatic CMT and vincristine neuropathy has been previously reported, the present case is of note because the reversible neuropathy occurred after five doses of vincristine, suggesting that possible more people suffering vincristine neurotoxicity may have underlying and asymptomatic CMT. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15382281     DOI: 10.1002/pbc.20123

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy.

Authors:  Sinan Akbayram; Cihangir Akgun; Murat Doğan; Refah Sayin; Huseyin Caksen; Ahmet Faik Oner
Journal:  Indian J Pediatr       Date:  2010-06-08       Impact factor: 1.967

2.  Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy.

Authors:  Laurence Meyer; Christine Patte-Mensah; Omar Taleb; Ayikoe Guy Mensah-Nyagan
Journal:  Cell Mol Life Sci       Date:  2010-04-30       Impact factor: 9.261

3.  Neuropathic pain during treatment for childhood acute lymphoblastic leukemia.

Authors:  Doralina L Anghelescu; Lane G Faughnan; Sima Jeha; Mary V Relling; Pamela S Hinds; John T Sandlund; Cheng Cheng; Deqing Pei; Gisele Hankins; Jennifer L Pauley; Ching-Hon Pui
Journal:  Pediatr Blood Cancer       Date:  2011-02-11       Impact factor: 3.167

4.  Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1).

Authors:  Patrick P Hess; Monica S Ventura Ferreira; Benjamin Rolles; Martin Kirschner; Florian Holtbernd; Mareike Tometten; Tim H Brümmendorf; Fabian Beier
Journal:  Clin Case Rep       Date:  2022-05-05

Review 5.  Neurotoxicity of chemotherapeutic and biologic agents in children with cancer.

Authors:  Kevin C De Braganca; Roger J Packer
Journal:  Curr Neurol Neurosci Rep       Date:  2008-03       Impact factor: 5.081

6.  Acute neurotoxicity following vincristine due to Charcot-Marie-Tooth disease in a young child with medulloblastoma.

Authors:  Trisha Kissoon; Sridharan Gururangan; John Sladky
Journal:  Neurooncol Pract       Date:  2019-03-18

7.  Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia.

Authors:  Lihua Yang; Lihua Yu; Xinxin Chen; Yanqun Hu; Bin Wang
Journal:  Med Sci Monit       Date:  2015-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.